key: cord-0762686-bb6qv6go authors: Talbot, Pierre J.; Paquette, Jean‐Sébastien; Ciurli, Cristina; Antel, Jack P.; Ouellet, France title: Myelin basic protein and human coronavirus 229E cross‐reactive T cells in multiple sclerosis date: 2004-10-08 journal: Ann Neurol DOI: 10.1002/ana.410390213 sha: a647afd1a53df9ca604f5dd51094c514153c1db7 doc_id: 762686 cord_uid: bb6qv6go Multiple sclerosis (MS) is an inflammatory demyelinating neurological disease in which autoreactive T lymphocytes sensitized to myelin components of the central nervous system are postulated to contribute to pathogenesis. The possible relevance of molecular mimicry between a human coronavirus and the myelin basic protein component of myelin in the generation of this autoimmune reaction was evaluated. Myelin basic protein– and virus‐reactive T‐cell lines were established from 16 MS patients and 14 healthy donors and shown to be mostly CD4(+). In contrast to healthy donors, several T‐cell lines isolated from MS patients showed cross‐reactivity between myelin and coronavirus antigens. Overall, 29% of T‐cell lines from MS patients (10 donors) but only 1.3% of T‐cell lines from normal control subjects (2 donors) showed an HLA‐DR‐restricted cross‐reactive pattern of antigen activation after in vitro selection with either myelin basic protein or human coronavirus strain 229E antigens. Moreover, reciprocal reactivities were only observed in MS patients (4 donors). This establishes molecular mimicry between a common viral pathogen, such as this human coronavirus, and myelin as a possible immunopathological mechanism in MS and is consistent with the possible involvement of more than one infectious pathogen as an environmental trigger of disease. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by multifocal regions of inflammation and myelin destruction [ 11. Clinical disease onset is most common in young adults. Disease prevalence is unevenly distributed geographically. Available evidence suggests that the etiology of MS is multifactorial and probably involves a combination of genetic susceptibility and environmental triggering factors [2] . Genetic predisposition may involve immune response genes such as those encoded by the major histocompatibility complex and T-cell receptor (TCR) complex gene regions [3, 41. However, the low concordance rate among monozygotic twins and epidemiological studies also implicate environmental factors, with microbial infections the most commonly cited triggering event associated with MS [5] . Repeated attempts have been made to identify an MS-linked pathogen. More than a dozen different viruses have been associated with MS over the years, without a clear causal relationship having yet been established [6] . Coronaviruses appear in the long list of candidates implicated in disease etiology. These enve-trathecal compartment of MS patients compared to control subjects . The mechanism underlying this activation of myelin-reactive T cells remains obscure. Interestingly, coronavirus infection of experimental animals leads to the activation of similar autoreactive T cells, which when transferred to naive animals, triggered experimental allergic encephalomyelitis (EAE), an autoimmune disease that is also used as a model for MS and is usually induced by the injection of myelin basic protein (MBP) or proteolipid protein (PLP) in adjuvant [2O] . Although the mechanism involved in such virus-induced autoimmunity is not known, molecular mimicry was suggested as an underlying triggering event [21, 221 . Indeed, molecular mimicry has often been proposed to be involved in the pathogenesis of MS, although experimental evidence has thus far been lacking. Presumably, the sharing of amino acid sequences between a virus and a self-antigen, such as MBP, could result in the activation by the infectious agent of T lymphocytes that recognize the shared sequences. Such T cells may be able to recognize the self-antigen, with immunopathological consequences, with or without an accompanying persistent viral infection. Such shared sequences between various viruses and MBP and PLP were reported several years ago, although biological consequences were not identified [23, 241 . W e also recently found such structural mimicry between a nonstructural protein of the 229E strain of human coronavirus (HCV-229E) and a region of MBP that is close to the immunodominant 84-102 site observed in MS patients [25] and is known to be encephalitogenic in experimental animals [26] . W e hypothesized that molecular mimicry between this group of common respiratory pathogens and myelin constituents could underlie the initiation, persistence, and/or recurrence of the CNS-directed autoreactive immune response associated with MS. According to this hypothesis, MS would be triggered in individuals who are genetically predisposed to mount an immune response to sequences of an infecting pathogen, such as the human coronavirus, that are shared with myelin antigens. Thus, we reasoned that MS patients would preferentially express virusmyelin cross-reactive T cells. Sixteen patients diagnosed with MS were selected at random: 7 patients showed chronic progression and 9, relapsingremitting disease. Fourteen healthy donors were selected at random as control subjects. Donors were between 24 and 66 years old, with a mean age of 36 years. Their histocornpatibility profiles were established serologically for human leukocyte antigen (HLA) class 11 antigens and the HLA-DR assignment was confirmed with a molecular assay (Table 1) . Human MBP was prepared from a normal male adult human brain (Montreal Brain Bank, Douglas Hospital, Verdun, Qukbec, Canada) according to the procedure of Cheifetz and Moscarello [27] . Purity was monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis: The expected single band of 21 kd was observed by Coomassie blue staining. A lyophilized stock was stored at -20°C and reconstituted to a concentration of 1 mg/ml in complete RPMI culture medium (described below) and scored at 4°C. HCV-229E, obtained from the American Type Culture Collection (ATCC; Rockville, MD), was propagated in the human embryonic lung cell line L132 [26] . Human coronavirus OC43 (HCV-OC43), also obtained from ATCC, was propagated in the human rectal tumor cell line HRT-18 [28] . Viral antigens were prepared from L132 cells infected with HCV-227E at an MOI of 0.01 at 33°C for 43 hours or HRT-18 cells infected with HCV-OC43 at an MOI of 0.004 at 33°C for 72 hours. Control antigens were prepared from parallel cultures of uninfected L132 or HRT-18 cells, respectively. The cells were lysed in the culture medium by three cycles of freezing at -70°C and thawing at 37"C, clarified at 9,600 g for 20 minutes to yield viral or control antigens, which were stored in aliquots at -70°C. Before use, infectious virus in the viral antigen preparations ( lo6 tissue culture infectious doses 50% [TCID5,] /ml) was inactivated by exposure to ultraviolet light (ulrraviolet illuminator, model 3-3000, Fotodyne, New Berlin, WI) for 7 minutes. T-cell lines were prepared according to a modification of the method of Pette and colleagues [ B ] . Briefly, peripheral blood lymphocytes were separated by FicolllHypaque (Pharmacia) density gradient centrifugation and resuspended at 2 X lo6 cells/ml in complete culture medium (Gibco) (WMI containing 2 mM l,-glutamine, 100 unitslml of penicillin, 100 pg/ml of streptomycin, 10 mM HEPES, 50 pM 2mercaptoethanol, 5% (vol/vol) heat-inactivated pooled AB serum [Pel-Freez, Brown Deer, WI], and 5% (vol/vol) heatinactivated [at 56°C for 30 minutes] autologous serum). Cells were seeded at 2 X loi cells per well (in 0.1 ml) into 76-well round-bottom microtiter plates (ICN/Flow), to which either MBP or viral antigen was added at a final concentration of 30 pg/ml (3 pgiwell) for MBP or a final dilution of 1/25 for viral antigens. After 3 to 4 days of incubation in a humidified atmosphere containing 5% (vol/vol) carbon dioxide, 0.1 ml of culture medium per well supplemented with 40 units of human recombinant interleukin-2 (Immunex, Seattle, WA) per milliliter was added and this was repeated every 3 to 4 days for a total of 14 days. Primary T-cell lines were screened for antigen-dependent proliferation. The T-cell lines in microtiter plates were washed twice with serum-free complete culture niediuin to remove free interleukin-2 (centrifugations were at 1,OOOg for 10 minutes), resuspended in 0.1 ml of complete culture medium per well, and split into two new 96-well round-bottom microtiter plates (50 pl/well). Autologous peripheral blood lymphocytes prepared as described above and irradiated with 2500 rads were added (1-2 X 10' cells in 50 pUwe11) as antigen-presenting cells in both microtiter plates. One of the two plates also received specific antigen, either MBP or viral antigens (same quantities as described above, in 10 pl/well), and the other plate received serumfree complete culture medium or L132 cell lysates in culture medium (10 pllwell). The cells were fed human recombinant interleukin-2 every 3 to 4 days for a total of 14 days, as described above. Antigen-specific T-cell lines were selected for expansion and proliferation assays. Cells were washed twice to remove free interleukin-2 and restimulated at a concentration of 2 X lo5 cells/ml in complete culture medium to which irradiated antigen-presenting cells (ratio of 5: I) and antigen were added. Proliferation assays described below were performed on an aliquot of these cells. Human recombinant interleukin-2 was added to the remaining cells every 3 to 4 days for a total of 14 days, as described above. This antigen restimulation protocol was repeated one to three times, for a total of three to five in vitro stimulations. Proliferation assays were performed by adding 1 X lo/' T cells per well into 96-well round-bottom microtiter plates to which irradiated antigen-presenting cells and various antigens were added separately in complete culture medium (duplicate or triplicate wells for each antigen, 0.1 ml/well). These specific and control antigens were MBP (4-12 pgiwell; 4 pg for MBP-reactive lines and 8 pg for virus-reactive lines were experimentally established as optimal), viral antigens in infected cell lysates (final dilution 1 / 10 to 1 / 50; optimal dilution 1 /25 for virus-reactive lines), tetanus toxoid (1 pg previously tested to be optimal), appropriate dilutions of uninfected cell lysates, and serum-free complete culture medium. ) incorporated in the presence of specific antigen over its control and a value above 3.0, with at least 1,000 cpm incorporated, was considered significant. Dose-response curves were performed for each antigen and the observed proliferation was found to gradually increase up to a specific amount of anti-gen (described above as optimal) and either remain stable or decrease if more antigen was used. MBP and viral anrigens used in proliferation assays were prepared as described above. Peripheral blood lymphocytes from the 30 donors described in Table 1 Of interest, there was no relationship between severity of neurological dysfunction or MS diagnosis and cross-reactivity patterns, which involved as many patients with an Expanded Disability Status Scale (EDSS) score lower than 5 as patients with an EDSS score equal to or higher than 5 (data not shown) and were observed in patients with both the relapsing-remitting and the chronic progressive disease (see Table 1 ). Although there was no apparent correlation between HLA type and reactivity patterns, it is interesting to note that the presumably more pathologically MBP lost their reactivity to MBP, even though they did react with virus (data not shown). This reactivity was not antigen independent since it was not observed with antigen-presenting cells only or with the control antigen (tetanus toxoid). Loss of reactivity to antigen was not observed with T-cell lines selected in the presence of virus. Two (PI and P10) of the 3 MS patients from whom this unusual T-cell reactivity profile was observed did not yield T-cell lines with cross-reactivity patterns involving both MBP and virus, as 10 other MS patients did. Loss of reactivity to MBP used as an in vitro selecting antigen has been previously observed and was accompanied by the acquisition of reactivity to measles virus [30] . It remains possible that these cells are indeed virus-MBP cross-reactive but have become nonresponsive to MBP, posibly because of suppressor epitopes found on this molecule and not on the virus. Indeed, T-cell lines and clones were recently reported to be generated at a higher frequency and proliferate better with a synthetic peptide homologous to an immunodominant epitope of MBP rather than the whole molecule [31] . In a preliminary verification of clonality, we used a semiquantitative reverse transcriptase-polymerase chain reaction procedure [32] to identify the Vp molecule on the TCR of 2 MBP-reactive T-cell lines obtained from 1 MS patient (P9). The T-cell line that recognized only MBP exclusively expressed the Vp4 chain and the T-cell line that reacted to both MBP and HCV-229E only expressed the Vpl3 molecule (data not shown). The proliferative responses to MBP and viral antigens were blocked by monoclonal antibodies to HLA class II antigens (for example, stimulation indices of 118 to MBP and 7.2 to virus of an MBP-reactive line were reduced to 0.73 and 1.1, respectively, while an isotype control antibody had no effect), and were not observed with HLA-mismatched antigen-presenting cells, which is consistent with an HLA-restricted response (data not shown). HLA-DR was identified as the restriction element, as previous studies also showed with MBP-reactive T cells [29] . Finally, it was of interest to evaluate the virus specificity of the T-cell lines that reacted to both MBP and HCV-229E antigens. For that purpose, MBPor HCV-229E-selected, cross-reactive T-cell lines obtained from 6 patients (PIl-PlG) (see Table 2 ) were also tested for reactivity to HCV-OC43 antigens. We observed no cross-reactivity to this other human coronavirus serotype, despite the fact that donors were sero-positive for this virus and HCV-OC43-reactive T-cell lines could be generated from the MS patient for whom it was tried (PI 3). This Observation strengthens the possibility that the observed cross-reactivity patterns are the result of molecular mimicry between HCV-229E antigens (or possibly vi rus-induced antigens) and MBP. The observation of an HLA-restricted proliferation to both myelin and viral antigens of T-cell lines is consistent with dual specificities of the cross-reactive T cells for MBP and virus. Since less than 10% of the culture wells contained antigen-reactive T cells, the Poisson distribution suggests that an antigen-specific T-cell line derived from an individual microculture well most likely represented a monoclonal response to the myelin or viral antigen, as reported by others [16] . The detection of a unique Vp molecule on the TCR of a T-cell line that recognized both MBP and viral antigens is also consistent with clonality, although this will need to be confirmed by sequencing of the variable regions of the TCR from several cross-reactive T-cell lines. The possibility that some of the observed cross-reactive patterns resulted from the selection of independent virusand MBP-reactive T cells present in the overall population by either virus or MBP antigens cannot be formally excluded but would in itself also be an interesting observation since its preferential occurrence in MS patients is consistent with a possible pathological relevance. The often lower stimulation indices observed with the heterologous antigen compared to the homologous selecting antigen (see Fig, data The frequent MBP reactivity of MS patient-derived T cells selected with in vitro virus exposure is consistent with the possibility that the activation of at least a portion of the MBP-reactive T cells observed in both the periphery and the CNS of MS patients [16] could have been triggered in some of these patients by an otherwise innocuous respiratory coronavirus infection. There was no difference in frequency of T-cell cross-reactivity between patients with the relapsing form of disease compared to those with progressive disease, and no correlation with severity of neurological dysfunction. This suggests that development of crossreactivity is not a direct consequence of CNS tissue injury. Of interest, T-cell lines from 8 MS patients showed MBP reactivity after selection with virus. Five of these patients bear che HLA-DR2 haplotype presumably as-sociated with genetic susceptibility to disease, although 3 other MS patients and 6 control subjects were also HLA-DR2' and showed no virus-myelin T-cell crossreactivity. This suggests that cross-reactivity is not a direct consequence of the presence of this HLA haplotype. It is also noteworthy that reciprocal cross-reactivities ( The coronavirus-myelin T-cell cross-reactivity patterns observed with much increased frequency in MS patients compared to control subjects, and which were specific for one of the two human coronavirus serotypes, are consistent with the molecular mimicry hypothesis of MS pathogenesis. Our finding that such cross-reactivity can occasionally be found in some control donors raises the issue of what prevents many individuals with autoreactive T cells from developing autoimmune disease [33] . Although the identity of the cross-reactive epitopes remains to be determined. it has now been reDorted number of T-cell clones studied, or the difficulty in predicting all relevant viral epitopes. Indeed, the identification of the biologically relevant cross-reactive epitopes between human coronavirus and MBP may in part require the use of purified proteins and peptides. Such studies are now in progress. Moreover, it will be important to look for the presence of such virus-myelin cross-reactive T cells within the CNS of MS patients. Our current findings regarding T-cell cross-reactivity between the human coronavirus and the myelin antigen MBP in some MS patients could be extended to numerous pathogens [21, 22, 361 and other endogenous CNS antigens, such as PLP, myelin-associated glycoprotein, myelin oligodendrocyte glycoprotein, cyclic-nucleotide phosphodiesterase [38] , and aB-crystallin [XI] , and this may account for the lack of coronavirus-MBP cross-reactive patterns in some MS patients. Virus-induced, T cell-mediated autoimmunity by molecular mimicry provides a unifying hypothesis that could explain both the suspected genetic involvement of immune response genes and the difficulty in associating one specific pathogen with MS. It is also consistent with the reported associations between viral infections, including those of the upper respiratory tract, and exacerbations of MS [40] , as well as with the beneficial effects on MS patients of interferon beta [41-431, which has among its many other actions an antiviral property. The authors are grateful to Manon Blair and Francine Lamhert for expert technical assistance, to Elyse B&in for her invaluable a s s k tance in the collection of experimental samples from our donors, distantly related viruses may not require striking StrUCtural homologies, and that apparently unrelated peptides can stimulate the same T lymphocytes, albeit to different degrees [341' Moreover' Only four native MBP residues were shown to be capab1e Of MBPreactive T cells [35] . Such studies recently culminated to Dr Pierre Duquette (H6pital Notre-Dame, Montrtal) for his in the elegant identification of viral peptides that could activate MBP-reactive T-cell clones generated from MS patients [36] . The cross-reactive sequences were predicted from the experimentally determined structural motifs required for binding of a peptide homologous to the immunodominant domain of MBP to HLA-DR2 molecules [37] , which have been associated with genetic susceptibility for the development of MS. Peptides that could activate T-cell clones specific for the irnmunodominant epitope of MBP were from diverse pathogens, some of which have been associated with MS: herpes simplex virus, Epstein-Barr virus, adenovirus type 12, influenza virus type A, and reovirus type 3, as well as Pseudomonus uemginosu. Interestingly, a peptide from the human coronavirus was predicted as bearing the necessary structural requirements, although it could not activatate the T-cell clones studied. This may be a reflection of the experimental bias toward the immunodominant epitope on MBP, the limited help in the selection of some MS patients, to Dr Rafick-Pierre S6kaly (Institur de Recherches Cliniques de Monrr6al) for graciously providing the interleukin-2 used in this study and for allowing us to share his expertise in the molecular characterization of T-cell receptors, to Marcel Desrosiers for cytofluorometty, to Francine pathogenesis of multiple sclerosis. Lancet 2. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis-a critical overview Human leukocyte antigen .studies in multiple sclerosis Association of susceptibility to multiple sclerosis with T C R genes Epidemiologic evidence for multiple sclerosis as an infection. C h i Implicarion of viruses in multiple sclerosis Human coronaviruses-a brief review Coronavirus infects and causes demyelination in primate central nervous system lntracisternal virusdike particles in the brain of a multiple sclerosis patient Two coronavituses isolated from central nervous system tissue of two multiple sclerosis patients Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients Differential susceptibility of cultured neural cells to the human coronavirus OC43 Neurotropism of human coronavirus 229E Human coronavirus gene expression in the brains of multiple sclerosis patients Detection of coronavirus RNA and antigen in inultiplc sclerosis brain Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and protealipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis T-cell and 5-cell responses to myelin-oligodendrucyte glycoprotein in multipie sclerosis The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis Reactivity to myelin antigens in multiple sclerosis-peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis Molecular mimicry and autoimmune disease Molecular mimicry: a mechanism for autoimmune injury Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis Analogous amino acid sequences in myelin proteolipid and viral proteins an immunodominant myelin basic protein epitope in multiple sclerosis Sequence analysis of human coronavirus 229E messenger KNAs 4 and 5-evidence for polymorphism and homology with myelin basic prorein Effect of bovine basic protein charge microheterogeneity on protein-induced aggregation of unilamellar vesicles containing a mixture of acidic and neutral phospholipids Sequence analysis of the membrane protein gene of human coronavirus 0c4.3 and evidence for 0-glycosylation Myelin basic proteinspecific T lymphocyte lines from MS patients and healthy individuals Peptide specificities of myelin basic protein-reactive human T-cell clones T lymphocyte lines and clones selected against synthetic myelin basic prorein 82-102 peptide from Japanese multiple sclerosis patients Human T c e k respond to mouse mammary tumor virus encoded superantigen-V-beta restriction and conserved evolutionary features Tolerance, danger, and the extended family Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses Minimum structural requirements for peptide presentation by major histocompatibility complex class I1 molecules-implications in induction of autoimmunity Molecular mimicry in Tcell mediated autoirntnunity: viral peptides activate human T cell clones specific for myelin basic protein Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones T-cell-reactivity against CNI'ase (a minor myehn component) in multiple sckrosis patienrs and normals The small heat-shock protein aB-crystallin as candidate autoantigen in inultiple sclerosis Influence of infection on exacerbations of multiple sclerosis Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, pfacebocontrolled trial Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. 11. M N analysis results of a multicenter, randomized, double-blind, placebo-controkd trial Results of a phase 111 trial of IM recombinant beta interferon as treatment for MS